Ergebnisbericht 2010/11 - Helmholtz-Zentrum für Infektionsforschung

WISSENSCHAFTLICHER ERGEBNISBERICHT | TWINCORE, Zentrum für Experimentelle und Klinische Infektionsforschung GmbH
Vollständige Liste aller von Mitarbeiterinnen und Mitarbeitern
am TWINCORE in 2010 und 2011 veröffentlichter
und in Druck befi ndlicher Publikationen
Forschungsgruppe um Prof. Kalinke
• 1. Williams SK, Fairless R, Weise J, Kalinke U, Schulz-Schaeffer W &
Diem R (2011) Neuroprotective effects of the cellular prion protein in
autoimmune optic neuritis. American Journal of Pathology (in press).
• 2. Gratz MS, Suezer Y, Kremer M, Volz A, Majzoub M, Hanschmann
KM, Kalinke U, Schwantes A & Sutter G (2011) N1L is a virulence
factor of ectromelia virus and essential for in vivo spread upon
respiratory infection. Journal of Virology (in press).
• 3. Grabski E, Waibler Z, Schule S, Kloke BP, Sender LY, Panitz S,
Cichutek K, Schweizer M & Kalinke U (2011) Comparative analysis
of transduced primary human dendritic cells generated by the use
of three different lentiviral vector systems. Molecular Biotechnology
47(3), 262-269.
• 4. Kochs G, Bauer S, Vogt C, Frenz T, Tschopp J, Kalinke U &
Waibler Z (2010) Thogoto virus infection induces sustained type I
interferon responses that depend on RIG-I-like helicase signaling of
conventional dendritic cells. Journal of Virology 84(23), 12344-12350.
• 5. Frenz T, Waibler Z, Hofmann J, Hamdorf M, Lantermann M, Reizis
B, Tovey MG, Aichele P, Sutter G & Kalinke U (2010) Concomitant
IFNAR-triggering of T cells and of DC is required to promote
maximal MVA-induced T-Cell expansion. European Journal of
Immunology 40(10), 2769-2777.
• 6. Goossens P, Gijbels MJ, Zernecke A, Eijgelaar W, Vergouwe MN,
van der Made I, Vanderlocht J, Beckers L, Buurman WA, Daemen
MJ, Kalinke U, Weber C, Lutgens E & de Winther MP (2010) Myeloid
type I interferon signaling promotes atherosclerosis by stimulating
macrophage recruitment to lesions. Cell Metabolism 12(2), 142-153.
• 7. Lang PA, Recher M, Honke N, Scheu S, Borkens S, Gailus N,
Krings C, Meryk A, Kulawik A, Cervantes-Barragan L, Van Rooijen
N, Kalinke U, Ludewig B, Hengartner H, Harris N, Häussinger D,
Ohashi PS, Zinkernagel RM & Lang KS (2010) Tissue macrophages
suppress viral replication and prevent severe immunopathology in
an interferon-I-dependent manner in mice. Hepatology 52(1), 25-32.
• 8. Prinz M & Kalinke U (2010) New lessons about old molecules: how
type I interferons shape Th1/Th17-mediated autoimmunity in the
CNS. Trends in Molecular Medicine 16(8), 379-386. Review.
• 9. Murikinati S, Juttler E, Keinert T, Ridder DA, Muhammad S,
Waibler Z, Ledent C, Zimmer A, Kalinke U & Schwaninger M (2010)
Activation of cannabinoid 2 receptors protects against cerebral
ischemia by inhibiting neutrophil recruitment. FASEB Journal 24(3),
788-798.
• 10. Sender LY, Gibbert K, Suezer Y, Radeke HH, Kalinke U & Waibler
Z (2010) CD40 ligand-triggered human dendritic cells mount
interleukin-23 responses that are further enhanced by danger
signals. Molecular Immunology 47(6), 1255-1261.
• 11. Al Moussawi K, Ghigo E, Kalinke U, Alexopoulou L, Mege JL
& Desnues B (2010) Type I interferon induction is detrimental
during infection with the Whipple’s disease bacterium, Tropheryma
whipplei. PLoS Pathogens 6(1): e1000722.
• 12. Ilchmann A, Burgdorf S, Scheurer S, Waibler Z, Nagai R, Wellner
A, Yamamoto Y, Yamamoto H, Henle T, Kurts C, Kalinke U, Vieths S
& Toda M (2010) Glycation of a food allergen by the Maillard reaction
enhances its T-cell immunogenicity: role of macrophage scavenger
receptor class A type I and II. Journal of Allergy and Clinical
Immunology 125(1), 175-183 e171-111.
145
• 13. Kern M, Popov A, Scholz K, Schumak B, Djandji D, Limmer
A, Eggle D, Sacher T, Zawatzky R, Holtappels R, Reddehase MJ,
Hartmann G, Debey-Pascher S, Diehl L, Kalinke U, Koszinowski U,
Schultze J & Knolle PA (2010) Virally infected mouse liver endothelial
cells trigger CD8+ T-cell immunity. Gastroenterology 138(1), 336-346.
• 14. Malinarich FH, Grabski E, Worbs T, Chennupati V, Haas JD,
Schmitz S, Candia E, Quera R, Malissen B, Förster R, Hermoso M
& Prinz I (2010) Constant TCR triggering suggests that the TCR
expressed on intestinal intraepithelial γδ T cells is functional in vivo.
European Journal of Immunology 40(12), 3378-88.
• 15. Schneider CK, Salmikangas P, Jilma B, Flamion B, Todorova LR,
Paphitou A, Haunerova I, Maimets T, Trouvin JH, Flory E, Tsiftsoglou
A, Sarkadi B, Gudmundsson K, O’Donovan M, Migliaccio G, Ancans
J, Maciulaitis R, Robert JL, Samuel A, Ovelgonne JH, Hystad M, Fal
AM, Lima BS, Moraru AS, Turcani P, Zorec R, Ruiz S, Akerblom
L, Narayanan G, Kent A, Bignami F, Dickson JG, Niederwieser D,
Figuerola-Santos MA, Reischl IG, Beuneu C, Georgiev R, Vassiliou
M, Pychova A, Clausen M, Methuen T, Lucas S, Schussler-Lenz M,
Kokkas V, Buzas Z, MacAleenan N, Galli MC, Line A, Gulbinovic J,
Berchem G, Fraczek M, Menezes-Ferreira M, Vilceanu N, Hrubisko
M, Marinko P, Timon M, Cheng W, Crosbie GA, Meade N, di Paola
ML, VandenDriessche T, Ljungman P, D’Apote L, Oliver-Diaz O, Buttel
I & Celis P (2010) Challenges with advanced therapy medicinal
products and how to meet them. Nature Reviews Drug Discovery 9(3),
195-201. Review.
• 16. Buttel IC, Voller K & Schneider CK (2010) Immunogenicity and
its impact on benefi t/risk considerations in the authorisation of
biopharmaceuticals. Current Drug Safety 5(4), 287-292. Review.
• 17. Goetz KB, Pfl eiderer M & Schneider CK (2010) First-inhuman
clinical trials with vaccines-what regulators want. Nature
Biotechnology 28(9), 910-916. Review.
• 18. Schussler-Lenz M & Schneider CK (2010) [Clinical trials with
advanced therapy medicinal products]. Bundesgesundheitsblatt
Gesundheitsforschung Gesundheitsschutz 53(1), 68-74. Review.
Forschungsgruppe um Prof. Pietschmann
• 1. Frentzen A, Hüging K, Bitzegeio J, Friesland M, Haid S, Gentzsch
J, Hoffmann M, Lindemann D, Zimmer G, Zielecki F, Weber F,
Steinmann E & Pietschmann T (2011) Completion of hepatitis C virus
replication cycle in heterokaryons excludes dominant restrictions in
human non-liver and mouse liver cell lines. PLoS Pathog (in press).
• 2. Gentzsch J, Hinkelmann B, Kaderali L, Irschik H, Jansen R, Sasse
F, Frank R & Pietschmann T (2011) Hepatitis C virus complete
life cycle screen for identifi cation of small molecules with pro- or
antiviral activity. Antiviral Research 89(2),136-48. Epub 2010 Dec 15.
• 3. Montserret R, Saint N, Vanbelle C, Salvay AG, Simorre JP, Ebel
C, Sapay N, Renisio JG, Bockmann A, Steinmann E, Pietschmann
T, Dubuisson J, Chipot C & Penin F (2010) NMR structure and ion
channel activity of the p7 protein from hepatitis C virus. Journal of
Biological Chemistry 285(41), 31446-31461.
• 4. Steinmann E & Pietschmann T (2010) Hepatitis C virus P7 - a
viroporin crucial for virus assembly and an emerging target for
antiviral therapy. Viruses 2010 2(9), 2078-2095 (Review).
• 5. Bitzegeio J, Bankwitz D, Hueging K, Haid S, Brohm C, Zeisel MB,
Herrmann E, Iken M, Ott M & Baumert TF, Pietschmann T (2010)
Adaptation of hepatitis C virus to mouse CD81 permits infection of
mouse cells in the absence of human entry factors. PLoS Pathogens
6: e1000978.
• 6. Bürgel B, Friesland M, Koch A, Manns MP, Wedemeyer H,
Weissenborn K, Schulz-Schaeffer WJ, Pietschmann T, Steinmann
E & Ciesek S (2010) Hepatitis C virus enters human peripheral
neuroblastoma cells - evidence for extra-hepatic cells sustaining
hepatitis C virus penetration. Journal of Viral Hepatology Jun 23
[Epub ahead of print].